Bristol Myers Squibb has announced positive topline results from the registrational Phase 2 QUINTESSENTIAL trial of arlocabtagene autoleucel (arlo-cel; BMS-986393), a potential first-in-class autologous GPRC5D-directed CAR T cell therapy, in adult patients with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM). The trial met both its primary and key secondary endpoints, signaling a potentially meaningful new treatment option for a growing and underserved patient population who have exhausted currently available therapies, including prior BCMA-targeted treatment.

Clinical Takeaway

✔ Arlo-cel demonstrated a statistically significant and clinically meaningful overall response rate (ORR) in quadruple-class exposed RRMM patients with four or more prior lines of therapy, meeting the trial’s primary endpoint.

✔ Key secondary endpoints were also met, including complete response rate (CRR) in patients with four or more prior lines of therapy, and both ORR and CRR in patients with three or more prior lines of therapy.

✔ QUINTESSENTIAL is the first pivotal trial to evaluate a therapy specifically in quadruple-class exposed RRMM patients who have previously received BCMA-targeted therapy, representing a critical and previously unaddressed treatment gap.

✔ The safety profile of arlo-cel was consistent with that observed with other CAR T-cell therapies and other GPRC5D-targeting agents in multiple myeloma.

Drug Profile & Mechanism

  • Drug name: Arlocabtagene autoleucel (arlo-cel; BMS-986393)
  • Developer: Bristol Myers Squibb
  • Drug class: Potential first-in-class autologous GPRC5D (G protein-coupled receptor class C group 5 member D)-directed CAR T cell therapy
  • Mechanism: Arlo-cel is engineered to redirect a patient’s own T cells to recognize and eliminate myeloma cells expressing GPRC5D, a target distinct from BCMA, providing an alternative mechanism of action for patients whose disease has progressed after BCMA-directed treatment.
  • Administration: Designed as a single infusion autologous CAR T cell therapy; the treatment process involves T cell collection via leukapheresis, bridging therapy, CAR T cell manufacturing, lymphodepleting chemotherapy, arlo-cel infusion, and post-infusion monitoring.
Presented at the 2026 TANDEM MEETINGS Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®; February 4–7, 2026; Salt Lake City, UT, USA

Target Population

QUINTESSENTIAL enrolled adult patients with quadruple-class exposed relapsed and refractory multiple myeloma. Quadruple-class exposure was defined as prior treatment with all four of the following drug classes:

  • An immunomodulatory inhibitor (IMiD)
  • A proteasome inhibitor (PI)
  • An anti-CD38 therapy
  • A BCMA-targeted therapy

Notably, the trial also permitted enrollment of patients who had previously received CAR T cell therapies, reflecting the real-world clinical complexity of this heavily pretreated population. As combination regimens are increasingly used in earlier lines of myeloma treatment, more patients are becoming quadruple-class exposed and refractory earlier in their disease course, underscoring the need for novel targeted approaches in this setting.

Study Design

  • Trial name: QUINTESSENTIAL
  • ClinicalTrials.gov identifier: NCT06297226
  • Phase: Phase 2, registrational
  • Design: Open-label, multicenter, single-arm study
  • Indication under study: Quadruple-class exposed relapsed and refractory multiple myeloma
  • Key eligibility: Adults with RRMM who had received prior IMiD, PI, anti-CD38 therapy, and BCMA-targeted therapy; prior CAR T cell therapy was permitted
  • Historical significance: QUINTESSENTIAL is the first pivotal trial to evaluate a therapy in quadruple-class exposed RRMM patients following prior BCMA-targeted treatment

Endpoints

  • Primary endpoint:
    • Overall response rate (ORR), defined as best overall response (BOR) of partial response (PR) or better, in quadruple-class exposed patients who had received four or more prior lines of therapy
  • Key secondary endpoints:
    • Complete response rate (CRR) in quadruple-class exposed patients with four or more prior lines of therapy
    • ORR in quadruple-class exposed patients with three or more prior lines of therapy
    • CRR in quadruple-class exposed patients with three or more prior lines of therapy

Efficacy Outcomes

  • The trial met its primary endpoint: arlo-cel demonstrated a statistically significant and clinically meaningful ORR in quadruple-class exposed RRMM patients who had received four or more prior lines of therapy.
  • The trial met the key secondary endpoint of CRR in quadruple-class exposed patients with four or more prior lines of therapy.
  • Both ORR and CRR key secondary endpoints in patients with three or more prior lines of therapy were also met.
  • Specific numerical values for ORR and CRR were not disclosed in the topline press release; full data will be presented at an upcoming medical meeting.

Safety

  • The safety profile of arlo-cel was consistent with that of other CAR T-cell therapies and other GPRC5D-targeting therapies used in multiple myeloma.
  • No unexpected safety signals were reported in the topline announcement.
  • Detailed safety data, including rates of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and other GPRC5D-class adverse events, are anticipated to be disclosed at the forthcoming medical conference presentation.

Key Clinical Implications

✔ A growing post-BCMA unmet need: As combination therapies are deployed earlier in the myeloma treatment continuum, more patients are becoming quadruple-class exposed and refractory sooner, creating an urgent need for non-BCMA targeted salvage options.

✔ GPRC5D as a validated target beyond BCMA: The positive QUINTESSENTIAL results reinforce GPRC5D as a clinically meaningful therapeutic target for patients whose disease has progressed on or after BCMA-directed therapy, including prior CAR T cell treatment.

✔ First pivotal trial in this specific setting: QUINTESSENTIAL is the first registrational study designed and powered exclusively for quadruple-class exposed RRMM patients post-BCMA therapy, establishing a new benchmark for clinical trial design in this population.

✔ Single-infusion convenience with curative intent: As a single-infusion autologous CAR T cell therapy, arlo-cel offers a potentially transformative treatment modality compared with continuous or repeated dosing regimens, which may have practical implications for patient quality of life and treatment burden.

✔ Full data awaited: Clinicians should anticipate the forthcoming conference presentation for complete efficacy and safety data, including depth and durability of response, which will be critical in contextualizing arlo-cel’s clinical benefit relative to existing post-BCMA options.

Bottom Line

The QUINTESSENTIAL trial has demonstrated that arlocabtagene autoleucel (arlo-cel), a potential first-in-class GPRC5D-directed CAR T cell therapy, met both its primary and all key secondary endpoints in patients with quadruple-class exposed RRMM who had received prior BCMA-targeted therapy. These results position arlo-cel as a promising therapeutic advance for one of the most heavily pretreated and therapeutically challenging patient populations in oncology. As the first pivotal trial conducted in this specific post-BCMA, quadruple-class exposed setting, QUINTESSENTIAL sets a new clinical precedent. Full data, including granular efficacy and safety metrics, are expected to be presented at an upcoming medical meeting and will be instrumental in determining arlo-cel’s eventual role in the evolving myeloma treatment landscape.

Sources: